(Q27824846)

English

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

scientific article

In more languages

Statements

scholarly article

1 reference

13 November 2016

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells (English)

1 reference

13 November 2016

apoptotic process

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Wenle Xia

1

0 references

Catherine M Gerard

2

0 references

Leihua Liu

3

0 references

Nathalie M Baudson

4

0 references

Thierry L Ory

5

0 references

Neil L Spector

6

0 references

language of work or name

0 references

publication date

15 September 2005

0 references

0 references

24

0 references

6213-21

0 references

41

0 references

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

ErbB-targeted therapeutic approaches in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Cytokine-regulated expression of survivin in myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Mechanism of action of erbB tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Pleiotropic cell-division defects and apoptosis induced by interference with survivin function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

HBXIP functions as a cofactor of survivin in apoptosis suppression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

21 January 2018

Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208774

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.ONC.1208774

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Dimensions Publication ID

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Springer Nature article ID

10.1038/sj.onc.1208774

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27824846&oldid=1833531649"